Research programme: autoimmune disease therapeutics and diagnostics - Nodality/Pfizer
Latest Information Update: 31 Jan 2015
At a glance
- Originator Nodality; Pfizer
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 17 Apr 2013 Early research is ongoing in USA
- 09 Aug 2012 Early research in Autoimmune disorders in USA (unspecified route)